Immutep Announces New Clinical Data from Triple Combination Therapy in INSIGHT-003 Trial
Portfolio Pulse from Benzinga Newsdesk
Immutep announces positive clinical data from its INSIGHT-003 trial, evaluating eftilagimod alpha in combination with standard-of-care anti-PD-1 therapy and doublet chemotherapy for 1st line non-small cell lung cancer.
May 24, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep's positive clinical data from the INSIGHT-003 trial may boost investor confidence and potentially impact the stock price.
The positive clinical data from Immutep's INSIGHT-003 trial indicates progress in the development of their novel LAG-3 immunotherapies. This may lead to increased investor confidence and a potential positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100